ASH 2023 | FLT3-ITD-specific MRD predicts outcomes of chemotherapy in AML
Mark Levis, MD, PhD, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, discusses the QuANTUM-First trial (NCT02668653), which monitored measurable residual disease (MRD) levels using FLT3-ITD-specific assays in patients with acute myeloid leukemia (AML) following chemotherapy. Favorable treatment outcomes were observed in patients who achieved MRD negativity following two courses of chemotherapy, paving the way for personalized medicine based on post-treatment MRD levels. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Research Funding: FujiFilm, Astellas Global Pharma
Consultancy: Takeda, Menarini, Jazz, Daiichi-Sankyo, Bristol Myers Squibb, Amgen, Abbvie, Pfizer
